Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Lantheus stock on January 13th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 2/3/2025.
• Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 1/31/2025.
• Purchased $50,001 – $100,000 in shares of Hawaiian Electric Industries (NYSE:HE) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of Agios Pharmaceuticals (NASDAQ:AGIO) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of SpringWorks Therapeutics (NASDAQ:SWTX) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of Paragon 28 (NYSE:FNA) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of U.S. Physical Therapy (NYSE:USPH) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 1/29/2025.

Lantheus Price Performance

NASDAQ LNTH traded down $0.14 during trading hours on Thursday, reaching $81.96. The company’s stock had a trading volume of 775,901 shares, compared to its average volume of 792,759. The firm has a market capitalization of $5.70 billion, a price-to-earnings ratio of 13.64 and a beta of 0.44. Lantheus Holdings, Inc. has a 1-year low of $55.01 and a 1-year high of $126.89. The company’s 50-day moving average is $91.76 and its two-hundred day moving average is $98.13.

Institutional Trading of Lantheus

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in shares of Lantheus during the 4th quarter worth $36,183,000. Groupama Asset Managment purchased a new position in shares of Lantheus in the 3rd quarter valued at approximately $439,000. Swedbank AB increased its position in shares of Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after acquiring an additional 385,000 shares during the period. Keybank National Association OH acquired a new position in shares of Lantheus in the fourth quarter valued at about $27,526,000. Finally, Norges Bank purchased a new position in shares of Lantheus in the fourth quarter worth about $26,189,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $131.86.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.50% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.